EV/EBITDA
Updated 78h ago
Sector Performance
71th percentileCPT
19.3x
Sector Median
13.7x
Sector Avg
18.4x
Deep Analysis
The EV/EBITDA of 19.3x means that for every dollar of earnings before interest, taxes, depreciation, and amortization, the company's enterprise value is $19.30 — a higher multiple generally indicates a richer valuation relative to its underlying cash earnings.
This is well above the sector median of 13.6x, placing CPT in the 72th percentile among its peers, meaning it is more expensive than nearly three-quarters of comparable companies. Trend data is not available: year-over-year change is N/A, quarter-over-quarter change is N/A, and there is only a single historical value of 19.3x, so no direction can be assessed. The elevated level combined with the absence of any trend data suggests a valuation that already carries a premium with no recent evidence of improvement or deterioration, introducing uncertainty. This metric supports the overall CAUTIOUS verdict, as the above-median multiple implies a higher bar for future earnings growth to justify the current price.
Frequently Asked Questions
What does the EV/EBITDA tell investors about CPT?
A valuation multiple preferred by analysts for capital-intensive or leveraged businesses. Useful for cross-sector comparisons where earnings can be distorted by debt.
How is the EV/EBITDA calculated?
EV/EBITDA is calculated as: Enterprise Value / EBITDA.
Who are CPT's closest peers by EV/EBITDA?
The closest peers by EV/EBITDA include: LSPD (-24.2x), BRZE (-24.5x), EVGO (-25.7x), NIO (-36.8x), SNAP (-38.8x).
The Formula
Enterprise Value / EBITDA
Why It Matters
A valuation multiple preferred by analysts for capital-intensive or leveraged businesses. Useful for cross-sector comparisons where earnings can be distorted by debt.
Master CPT's Valuation
Get the complete institutional research report covering all fundamental and technical metrics.
View full CPT research report →CPT
19.3x
Sector Median
13.7x
Sector Avg
18.4x
How CPT's EV/EBITDA compares to sector peers.
Also Analyze
Not financial advice. Research tool only. Data may be delayed.